STUDY OF PHOTOSENSITIZER FOR ANTIBACTERIAL PHOTODYNAMIC THERAPY BASED ON CYCLODEXTRIN FORMULATION OF 133-N-(N-METHYLNICOTINYL)BACTERIOPURPURINIMIDE METHYL ESTER

Cationic bacteriochlorins are promising as antibacterial photosensitizers (PS) for antibacterial photodynamic therapy. Current work is devoted to the study of properties of new nanostructured cationic photosensitizer based on cyclodextrin dispersion of bacteriochlorine derivative – 133-N-(N-methylnicotinyl)-bacteriopurpurinimide methyl ester, for optimization of dispersion composition and selection of time interval between administration of the PS and photodynamic ttherapy of infected septic wounds. Specifics of absorption and fluorescence of PS in dependence of its concentration and proportions of components in dispersion was assessed. Pharmacokinetics and biodistribution of PS were studies in vivo in organs and tissues of intact mice and septic wounds infected with P. аeruginosa or S. aureus. The preliminary studies have shown high efficiency of antimicrobial photodynamic therapy of septic wounds with cyclodextrin dispersion of 133-N-(N-methylnicotinyl)-bacteriopurpurinimide methyl ester. Results of study of absorption and spectral and fluorescence properties of its drug formulation depending on its composition allowed to recommend the use of weight ratio 133-N-(N-methylnicotinyl)bacteriopurpurinimide methyl ester : cyclodextrin about 1:200 and addition of 0,1% Tween 80 to reduce aggregation. The study showed that 133-N-(N-methylnicotinyl)-bacteriopurpurinimide methyl ester was rapidly cleared from mouse blood circulation: more than 70% – for 2 h, 95% – for 1 day, more than 99% – for 6 days. About 98% was cleared from skin and muscles for 6 days. The long-term (up to 24 h) persistence of PS were observed in liver and kidneys, however more than 99% was cleared for 6 days. Thus, it may be supposed that elimination of PS form mice body is through kidneys and liver. After 24 h partial PS aggregation in tissues, particularly in skin and muscles, was observed. Thus, it may be supposed that the reduce of fluorescence intensity after 24 hand later was associated not only with its elimination from body but with its aggregation. Spectral and fluorescence studies showed that 133-N-(Nmethylnicotinyl)-bacteriopurpurinimide methyl ester selectively accumulated in septic wounds, fluorescence contrast was in the range of 3–4. The highest values of concentration and selectivity of its accumulation were achieved at 1.5–3 h after intravenous injection. The irradiation 2 h after injection provided high efficacy of the therapy of septic wounds.

antibacterial photodynamic therapy, 133-N-(N-methylnicotinyl)-bacteriopurpurinimide methyl ester, bacteriochlorine derivative, absorption, fluorescence, aggregation, cyclodextrin

1. Porphyrins as antimicrobial photosensitizing agents, in Photodynamic Inactivation of Microbial Pathogens: Medical and Environmental Applications, by eds M.R. Hamblin and G. Jori. London, 2011.

2. Banfi S., Caruso E., Buccafurni L., Battini V., Zazzaron S., Orlandi V. Antibacterial activity of tetraaryl-porphyrin photosensitizers: an in vitro study on Gram negative and Gram positive bacteria, Photochem. Photobiol, B., 2006, Vol. 85, p. 28.

3. Boyle-Vavra S., Labischinski H., Ebert C.C., Ehlert K., Daum R.S. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureusisolates, Antimicrob Agents Chemother., 2001, Vol. 45, pp. 280-287.

4. Roland K.L., Esther C.R., Spitznagel J.K. Isolation and characterization of a gene, pmrD, from Salmonella typhimurium that confers resistance to polymixin when expressed in multiple copies, Bacteriol., 1994, Vol. 176, pp. 589-597.

5. Harder K.J., Nikaido H., Matsuhashi M. Mutants of Escherichia coli that are resistant to certain beta-lactam compounds lack the ompF porin, Antimicrob Agents Chemother, 1981, Vol. 20, pp. 549-552.

6. Park Y.S., Lee H.B., Chin S., Han S.H., Hong S.G., Hong S.K., Kim H.Y., Uh Y., Shin H.B., Choo E.J., Han S.H., Song W., Jeong S.H., Lee K., Kim J.M. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems, Hosp. Infect., 2011, Vol. 79, p. 54.

7. Wainwright M. Photodynamic antimicrobial chemotherapy // Antimicrob Chemother, 1998, Vol. 42, pp. 13-28.

8. Friedrich C.L., Moyles D., Beveridge T.J., Hancock R.E. Antibacterial action of structurally diverse cationic peptides on Grampositive bacteria, Antimicrob Agents Chemother, 2000, Vol. 44, pp. 2086-2092.

9. Nikaido H. Prevention of drug access to bacterial targets: Permeability barrier and active efflux, Science, 1994, Vol. 264, pp. 362-368.

10. Leive L. The barrier function of the Gram-negative envelope, Ann NY Acad Sci, 1974, Vol. 235, pp. 109-129.

11. Bertoloni G., Rossi F., Valduga G., Jori G., Ali H., van Lier J.E. Photosensitising activity of water- and lipid-soluble phthalocyanines on prokaryotic and eukaryotic microbial cells, Microbios., 1992, Vol. 71, pp. 33-46.

12. Nakonieczna J., Michta E., Rybicka M., Grinholc M., GwizdekWiśniewska A., Bielawski K.P. Superoxide dismutase is upregulated in Staphylococcus aureus following protoporphyrin-mediated photodynamic inactivation and does not directly influence the response to photodynamic treatment, BMC Microbiol., 2010, Vol. 10, p. 323.

13. Tavares A., Carvalho C.M.B., Faustino M.A., Neves M.G., Tomé J.P., Tomé A.C., Cavaleiro J.A., Cunha A., Gomes N.C., Alves E., Almeida A. Antimicrobial photodynamic therapy: study of bacterial recovery viability and potential development of resistance after treatment, Mar. Drugs., 2010, Vol. 8, p. 91.

14. Caminos D.A., Spesia M.B., Pons P., Durantini E.N. Mechanisms of Escherichia coli photodynamic inactivation by an amphiphilic tricationic porphyrin and 5,10,15,20-tetra(4-N,N,N trimethylammoniumphenyl) porphyrin, Photochem. Photobiol. Sci., 2008, Vol. 7, pp. 1071.

15. Hamblin M.R., Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease, Photochem. Photobiol. Sci., 2004, Vol. 3, p. 436.

16. Wardlaw J.L., Sullivan T.J., Lux C.N., Austin F.W. Photodynamic therapy against common bacteria causing wound and skin infections, Vet., 2012, Vol. 192, p. 374.

17. Malik Z., Ladan H., Nitzan Y. Photodynamic inactivation of Gramnegative bacteria: problems and possible solutions, Photochem Photobiol B, 1992, Vol. 14, pp. 262-266.

18. Dai T., Huang Y.Y., Hamblin M.R. Photodynamic therapy for localized infections — state of the art, Photodiagn Photodyn Ther, 2009, Vol. 6, pp. 170-188.

19. Vera D.M., Haynes M.H., Ball A.R., Dai T., Astrakas C., Kelso M.J., Hamblin M.R., Tegos G.P. Strategies to potentiate antimicrobial photoinactivation by overcoming resistant phenotypes, Photochem Photobiol, 2012, Vol. 88, pp. 499-511.

20. Maisch T. Resistance in antimicrobial photodynamic inactivation of bacteria, Photochem Photobiol Sci, 2015, Vol. 14, pp. 1518-1526.

21. Giuliani F., Martinelli M., Cocchi A., Arbia D., Fantetti L., Roncucci G. In vitro resistance selection studies of RLP068/Cl, a new Zn(II) phthalocyanine suitable for antimicrobial photodynamic therapy, Antimicrob Agents Chemother, 2010, Vol. 54, pp. 637-642.

22. de Melo W.C., Avci P., de Oliveira M.N., Gupta A., Vecchio D., Sadasivam M., Chandran R., Huang Y.Y., Yin R., Perussi L.R., Tegos G.P., Perussi J.R., Dai T., Hamblin M.R. Photodynamic inactivation of biofilm: taking a lightly colored approach to stubborn infection, Expert Rev Anti Infect Ther, 2013, Vol. 11, pp. 669-693.

23. Ferreyra D.D., Reynoso E., Cordero P., Spesia M., Alvarez M.G., Milanesio M.E., Durantini E. Synthesis and properties of 5,10,15,20-tetrakis[4-(3-N,N-dimethylaminopropoxy)phenyl] chlorin as potential broad-spectrum antimicrobial photosensitizers, Photochem Photobiol B, 2016, Vol. 158, pp. 243-251.

24. Gad F., Zahra T., Francis K.P., Hasan T., Hamblin M.R. Targeted photodynamic therapy of established soft-tissue infections in mice, Photochem Photobiol Sci., 2004, Vol. 3, pp. 451-458.

25. Brusov S.S., Tiganova I.G., Romanova Yu.M., Grin M.A., Meerovich G.A. The process of photodynamic therapy for local foci of infection, Patent RF No. 2610566, 2017.

26. Ermolaeva S.A., Varfolomeev A.F., Chernukha M.Yu., et al. Bactericidal effects of non-thermal argon plasma in vitro, in biofilms and the animal model of infected wounds, J.Med. Microbiol., 2011, Vol. 60 (Pt.1), рр.75-83.

27. Tayana M.T., Gustavo B., Bruno H.V. Aggregation of aluminum phthalocyanine hydroxide in water/ethanol mixtures, J. Braz. Chem. Soc., 2014, Vol. 25(5), pp. 890-897.

28. Lastovoi A.P., Avramenko G.V. Spectral-Luminescent Properties of the Substituted Tetraazachlorins Solubilized in Solutions of Nonionic Surfactants, Makrogeterotsikly, 2013, Vol. 2, No. 2, pp. 137-143.

29. Dhami S., De Mello A.J., Rumbles G., Bishop S.M., Philips D., Beeby A. Phthalocyanine fluorescence at high concentration: dimers or reabsorption effect? Photochemistry and Photobiology, 1995, Vol. 61(4), pp. 341-346.